Pushkal Garg

Ochre Bio

Quin Wills

Ochre Bio has appointed Quin Wills as chief executive officer. Wills, Ochre’s founder, brings significant industry experience to the role. He most recently served as the company’s chief scientific officer, and previously founded and led an interdisciplinary genomics department as part of an Oxford University and Novo Nordisk collaborative institute.

Cancer Research UK

Samra Turajlić

Cancer Research UK has appointed Samra Turajlić as director of the Cancer Research UK Manchester Institute. Turajlić is an independent research group leader at the Francis Crick Institute and a consultant medical oncologist at the Royal Marsden NHS Foundation Trust. She also leads the UK immunotherapy consortium MANIFEST.

Microbiotica

Robert Tansley

Microbiotica has appointed Robert Tansley as chief medical officer. Tansley, a partner at Cambridge Innovation Capital, brings extensive life sciences experience to the role. He previously served as chief medical officer at KalVista and as founding chief executive officer of University of Copenhagen spin-out Avilex Pharma. He has also held roles at Sanofi, the MHRA and Roche.

Isomorphic Labs

Ben Wolf

Isomorphic Labs has appointed Ben Wolf as chief medical officer. Wolf has almost 20 years of biopharmaceutical experience and joins Isomorphic from Relay Therapeutics, where he served as chief medical officer. He was also previously chief medical officer at KSQ Therapeutics, and held positions at BluePrint Medicines, Amgen and Genentech.

Arbor Biotechnologies

Mikael Dolsten

Arbor Biotechnologies has appointed Mikael Dolsten to its board of directors. Dolsten most recently served as chief scientific officer and president of worldwide research, development and medical at Pfizer. He also previously held positions at Boehringer Ingelheim and AstraZeneca, and currently serves on the public boards of Agilent Technologies and Rocket Pharmaceuticals.

Clinigen

Paul Carter

Clinigen has appointed Paul Carter as non-executive chair of its board of directors. Carter holds almost 30 years of global biopharmaceutical industry leadership experience and previously served as executive vice president and chief commercial officer at Gilead Sciences. He was also head of GSK China, and serves on the boards of companies such as Memo Therapeutics and Kyowa Kirin.

AstriVax Therapeutics

Dieter Weinand

AstriVax Therapeutics has appointed Dieter Weinand as chair of its board of directors. Weinand brings extensive industry experience to the role, having previously served as chief executive officer at Bayer. He was also previously president, primary care, Canada/Asia-Pacific at Pfizer, and spent over ten years at Bristol Myers Squibb, most recently as president, intercontinental division.

Commit Biologics

Esper Boel

Commit Biologics has appointed Esper Boel as a member of its scientific advisory board. Boel is a molecular biologist with four decades of experience in international biopharmaceutical research and development. He previously spent 34 years at Novo Nordisk, most recently as the company’s corporate vice president and head of biotechnology.